CONGRESS OF THE EUROPEAN COLLEGE OF VETERINARY INTERNAL MEDICINE - COMPANION ANIMALS

Newsletter Boehringer Ingelheim




About Boehringer Ingelheim Animal Health
On January 1st, 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales. For more information, please visit www.boehringer-ingelheim.com

Boehringer Ingelheim Breakfast Symposium
Date: Friday 15 September
Time: 6.45 AM - 8.00 AM
Registration: No registration needed, accessible for all participants
Venue: InterContinental Malta, Room VENUS
Speaker: Prof. Dr. vet. med. Gerhard Wess, Ludwig-Maximilians-University Munich, Germany
Topic: The VALVE Study: Is Triple Therapy Superior to Double Therapy for heart failure?